Real-world data on lenalidomide dosing and outcomes in patients newly diagnosed with multiple myeloma: Results from the Canadian Myeloma Research Group Database

被引：0

作者：

Mian, Hira ^{[1
]}

LeBlanc, Richard ^{[2
]}

Louzada, Martha ^{[3
]}

Masih-Khan, Esther ^{[4
,5
]}

McCurdy, Arleigh ^{[6
]}

Venner, Christopher P. ^{[7
]}

Stakiw, Julie ^{[8
]}

Kardjadj, Moustafa ^{[4
]}

Jimenez-Zepeda, Victor H. ^{[9
]}

Sebag, Michael ^{[10
]}

White, Darrell ^{[11
]}

Aslam, Muhammad ^{[12
]}

Song, Kevin ^{[13
]}

Reiman, Anthony ^{[14
]}

Kotb, Rami ^{[15
]}

Gul, Engin ^{[4
]}

Reece, Donna ^{[4
,5
]}

机构：

[1] McMaster Univ, Hamilton, ON, Canada

[2] Univ Montreal, Maisonneuve Rosemont Hosp Res Ctr, Montreal, PQ, Canada

[3] London Reg Canc Ctr, London, ON, Canada

[4] Canadian Myeloma Res Grp, Vaughan, ON, Canada

[5] Princess Margaret Canc Ctr, Toronto, ON, Canada

[6] Ottawa Hosp, Ottawa, ON, Canada

[7] Univ Alberta, Cross Canc Inst, Edmonton, AB, Canada

[8] Univ Saskatchewan, Saskatoon Canc Ctr, Saskatoon, SK, Canada

[9] Univ Calgary, Arnie Charbonneau Canc Inst, Calgary, AB, Canada

[10] McGill Univ, Montreal, PQ, Canada

[11] Dalhousie Univ, Queen Elizabeth II Hlth Sci Ctr, Halifax, NS, Canada

[12] Allan Blair Canc Ctr, Regina, SK, Canada

[13] Vancouver Gen Hosp, BC Canc Agcy, Vancouver, BC, Canada

[14] St Johns Hosp, St John, NB, Canada

[15] Canc Care Manitoba, Winnipeg, MB, Canada

来源：

CANCER MEDICINE | 2023年 / 12卷 / 04期

关键词：

dosing; lenalidomide; multiple myeloma; transplant-ineligible; SURVIVAL; STRATEGY;

D O I：

10.1002/cam4.5245

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Using the Canadian Myeloma Research Group Database, a retrospective study of 167 newly diagnosed, transplant-ineligible patients with multiple myeloma (MM) that received lenalidomide-dexamethasone as front-line treatment was conducted to understand the impact of lenalidomide dosing. Starting dose modifications were common, 42% of patients started on lenalidomide <25 mg with normal renal function. During treatment course, 35% of patients required further dose reduction. Dose reductions in the first year did not have an impact on progression free survival or overall survival. Further studies need to be conducted to understand the impact of dosing strategies of anti-MM agents in the real world.

引用

页码：4357 / 4362

页数：6

共 50 条

[1] Real-world results of autologous stem cell transplantation in newly diagnosed multiple myeloma: a report from the Canadian Myeloma Research Group database
Cote, Julie
LeBlanc, Richard
Mian, Hira
Chu, Michael P.
McCurdy, Arleigh
Masih-Khan, Esther
Su, Jiandong
Jimenez-Zepeda, Victor H.
Song, Kevin
Louzada, Martha
White, Darrell
Sebag, Michael
Reiman, Anthony
Stakiw, Julie
Kotb, Rami
Bergstrom, Debra
Aslam, Muhammad
Kaedbey, Rayan
Venner, Christopher P.
Gul, Engin
Reece, Donna
[J]. BLOOD CANCER JOURNAL, 2023, 13 (01)
[2] Real-world results of autologous stem cell transplantation in newly diagnosed multiple myeloma: a report from the Canadian Myeloma Research Group database
Julie Côté
Richard LeBlanc
Hira Mian
Michael P. Chu
Arleigh McCurdy
Esther Masih-Khan
Jiandong Su
Victor H. Jimenez-Zepeda
Kevin Song
Martha Louzada
Darrell White
Michael Sebag
Anthony Reiman
Julie Stakiw
Rami Kotb
Debra Bergstrom
Muhammad Aslam
Rayan Kaedbey
Christopher P. Venner
Engin Gul
Donna Reece
[J]. Blood Cancer Journal, 13
[3] Lenalidomide Dosing and Outcomes in Transplant-Ineligible Patients with Newly-Diagnosed Multiple Myeloma: A Multi-Institutional Report from the Canadian Myeloma Research Group (CMRG) Database
Mian, Hira S.
Leblanc, Richard
Louzada, Martha L.
Masih-Khan, Esther
McCurdy, Arleigh
Venner, Christopher P.
Stakiw, Julie
Kardjadj, Moustafa
Jimenez-Zepeda, Victor H.
Sebag, Michael
White, Darrell J.
Aslam, Muhammad
Song, Kevin W.
Reiman, Anthony
Kotb, Rami
Gul, Engin
Reece, Donna E.
[J]. BLOOD, 2021, 138
[4] Real-World Results of Autologous Stem Cell Transplantation in Newly Diagnosed Patients with Multiple Myeloma: A Multi-Institutional Report from the Canadian Myeloma Research Group (CMRG) Database
Cote, Julie
Leblanc, Richard
Chu, Michael P.
McCurdy, Arleigh
Masih-Khan, Esther
Kardjadj, Moustafa
Jimenez-Zepeda, Victor H.
Song, Kevin
Louzada, Martha L.
Mian, Hira S.
White, Darrell
Sebag, Michael
Reiman, Anthony
Stakiw, Julie
Kotb, Rami
Bergstrom, Debra
Aslam, Muhammad
Kaedbey, Rayan
Venner, Christopher P.
Gul, Engin
Reece, Donna E.
[J]. BLOOD, 2022, 140
[5] The survival impact of maintenance lenalidomide: an analysis of real-world data from the Canadian Myeloma Research Group national database
Cherniawsky, Hannah M.
Kukreti, Vishal
Reece, Donna
Masih-Khan, Esther
McCurdy, Arleigh
Jimenez-Zepeda, Victor H.
Sebag, Michael
Song, Kevin
White, Darrell
Stakiw, Julie
LeBlanc, Richard
Reiman, Anthony
Aslam, Muhammad
Louzada, Martha
Kotb, Rami
Gul, Engin
Atenafu, Eshetu
Venner, Christopher P.
[J]. HAEMATOLOGICA, 2021, 106 (06) : 1733 - 1736
[6] Bortezomib, lenalidomide and dexamethasone in newly diagnosed multiple myeloma patients: a real-world study of China
Xu, Jingyu
Yan, Wenqiang
Fan, Huishou
Liu, Jiahui
Du, Chenxing
Deng, Shuhui
Sui, Weiwei
Xu, Yan
Qiu, Lugui
An, Gang
[J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S159 - S159
[7] Lenalidomide maintenance post-transplantation in newly diagnosed multiple myeloma: real-world outcomes and costs
Hari, Parameswaran
Ung, Brian
Abouzaid, Safiya
Agarwal, Amit
Parikh, Kejal
[J]. FUTURE ONCOLOGY, 2019, 15 (35) : 4045 - 4056
[8] Longitudinal Real-World Neuropathy and Patient-Reported Outcomes With Bortezomib and Lenalidomide in Newly Diagnosed Multiple Myeloma
Major, Ajay
Jakubowiak, Andrzej
Derman, Benjamin
[J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 (11): : E1000 - E1008
[9] Outcomes of transplant-ineligible myeloma patients using bortezomib/lenalidomide-containing regimens in the real world: a report from the Canadian Myeloma Research Group Database
Kaedbey, Rayan
Venner, Christopher
McCurdy, Arleigh
Masih-Khan, Esther
Kardjadj, Moustafa
Chu, Michael
Louzada, Martha
Jimenez-Zepeda, Victor
LeBlanc, Richard
Mian, Hira
Song, Kevin
Sebag, Michael
Stakiw, Julie
White, Darrell
Reiman, Anthony
Aslam, Muhammad
Kotb, Rami
Bergstrom, Debra
Gul, Engin
Reece, Donna E.
[J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S145 - S146
[10] Impact of Daratumumab-Containing Regimens in Outcomes of Subsequent Treatments of Relapsed Multiple Myeloma in Real-World Practice from the Canadian Myeloma Research Group Database
Leblanc, Richard
Venner, Christopher P.
Masih-Khan, Esther
Kardjadj, Moustafa
Chu, Michael P.
Jimenez-Zepeda, Victor H.
McCurdy, Arleigh
Song, Kevin
Sebag, Michael
Louzada, Martha L.
Mian, Hira S.
White, Darrell J.
Stakiw, Julie
Kotb, Rami
Reiman, Anthony
Aslam, Muhammad
Kaedbey, Rayan
Gul, Engin
Reece, Donna E.
[J]. BLOOD, 2022, 140 : 7192 - 7194

← 1 2 3 4 5 →